TipRanks
Xvivo Perfusion AB (SE:XVIVO)
:XVIVO
Want to see SE:XVIVO full AI Analyst Report?

Xvivo Perfusion AB (XVIVO) Price & Analysis

4 Followers

XVIVO Stock Chart & Stats

kr272.40
-kr4.00(-1.61%)
At close: 4:00 PM EDT
kr272.40
-kr4.00(-1.61%)

Bulls Say, Bears Say

Bulls Say
Organic Growth And Operating LeverageStrong organic growth across the first nine months, combined with higher EBITDA margins, indicates expanding adoption of XVIVO’s transplantation technologies. Sustained commercial momentum can strengthen operating leverage, fund continued innovation, and support broader customer penetration over the next several quarters.
Regulatory And Product ExpansionMeaningful regulatory progress expands the addressable market for Heart Assist Transport and reduces a key barrier to commercialization. EU approval enables broader center adoption, while the accepted U.S. PMA creates a pathway to a potentially important future growth platform, subject to approval.
Strong Balance Sheet And LiquidityVery low leverage and substantial liquidity give XVIVO flexibility to fund clinical trials, regulatory work, commercial expansion, and production capacity without relying heavily on external financing. This balance-sheet strength also lowers refinancing pressure and improves resilience while new products scale.
Bears Say
Component Shortages Constrain Kidney GrowthComponent shortages directly limit the company’s ability to convert existing kidney demand into revenue, making near-term growth dependent on resolving the updated-component transition. Even if described as temporary, constrained fulfillment can delay customer adoption and weaken momentum across the kidney franchise.
Services Revenue And Margin PressureThe sharp decline in services revenue and negative gross margin reduces the quality and predictability of consolidated earnings. Lower recovery volumes, delayed contracts, and investment in the surgical team may continue weighing on profitability until new service agreements convert into revenue.
Earnings Consistency Remains UnevenYear-to-year margin volatility makes current earnings power less predictable than the latest results alone suggest. Fluctuations in product mix, services performance, inventory effects, and commercial investment could continue to produce uneven profitability and complicate durable margin expansion.

Xvivo Perfusion AB News

XVIVO FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr160.10 and its highest was kr314.80 in the past 12 months.
    What is Xvivo Perfusion AB’s market cap?
    Xvivo Perfusion AB’s market cap is kr7.23B.
      When is Xvivo Perfusion AB’s upcoming earnings report date?
      Xvivo Perfusion AB’s upcoming earnings report date is Jan 28, 2027 which is in 97 days.
        How were Xvivo Perfusion AB’s earnings last quarter?
        Xvivo Perfusion AB released its earnings results on Oct 22, 2026. The company reported kr1.41 earnings per share for the quarter, beating the consensus estimate of kr0.651 by kr0.759.
          Is Xvivo Perfusion AB overvalued?
          According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Xvivo Perfusion AB pay dividends?
            Xvivo Perfusion AB does not currently pay dividends.
            What is Xvivo Perfusion AB’s EPS estimate?
            Xvivo Perfusion AB’s EPS estimate is 0.87.
              How many shares outstanding does Xvivo Perfusion AB have?
              Xvivo Perfusion AB has 31,499,470 shares outstanding.
                What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
                Xvivo Perfusion AB reported an EPS of kr1.41 in its last earnings report, beating expectations of kr0.651. Following the earnings report the stock price went down -1.412%.
                  Which hedge fund is a major shareholder of Xvivo Perfusion AB?
                  Currently, no hedge funds are holding shares in SE:XVIVO
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Xvivo Perfusion AB

                    Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.

                    Xvivo Perfusion AB (XVIVO) Earnings & Revenues

                    XVIVO Company Deck

                    XVIVO Earnings Call

                    Q3 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call was strongly positive overall, with 32% organic Q3 growth, improving EBITDA and cash flow, strong thoracic and heart momentum, major European and U.S. regulatory progress, and multiple expansion opportunities. The main challenges were temporary component and manufacturing-transfer constraints, weaker services revenue and margins, uncertainty around a major U.S. lung customer, reimbursement timing in Europe, competition in U.S. Liver, and planned near-term commercial investment that is expected to cause a slight margin dip.View all SE:XVIVO earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Getinge
                    ―
                    ―
                    Vitrolife AB
                    ―
                    ―
                    BICO Group AB Class B
                    ―
                    ―
                    SciBase Holding AB
                    ―
                    ―
                    Sedana Medical AB
                    ―
                    ―
                    Popular Stocks